期刊文献+

加味补阳还五汤对七氟烷麻醉处理后早期糖尿病肾病大鼠肾足细胞影响实验研究 被引量:5

Effect of the Modified Buyang Huanwu Decoction on the Early of the Diabetic Nephropathy Rats Podocyte after Anesthesia Induction with Sevoflurane Preconditioning
下载PDF
导出
摘要 目的:探讨加味补阳还五汤(MDIY)对七氟烷麻醉处理后的早期糖尿病肾病(DN)大鼠肾足细胞的影响。方法:将早期DN大鼠随机分为4组(每组n=16):MDIY组(A组),罗格列酮组(B组),MDIY+罗格列酮组(C组)和模型对照组(D组),另设正常大鼠(E组)为空白对照组。连续治疗7周,每天收集大鼠死亡数和葡萄糖(GLU)、肌酐(CR)、尿素氮(BUN)和尿微量白蛋白(UAL)。七氟烷麻醉处理后采集标本,通过苏木精和伊红染色(H&E)收集肾脏和肾病理变化检查。应用实RT-PCR和western blotting检测评估肾足突细胞各m-RNA的表达水平,包括nephrin、podocin、α-SMA和desmin的表达。结果:在治疗周期中,A组、B组和C组的GLU和UAL水平均低于D组(P<0.01),且7周后3组的GLU、CR和BUN水平也都远低于D组(P<0.05)。其中,C组的上述生化指标远低于A组和B组(P<0.05)。相比于正常SD大鼠,通过H&E染色,观察各组的肾小球疾病、慢性肾小管间质损伤和肾小球足细胞损伤的发病率。然而,只有C组显示更能优化改善上述损伤的发病率。在A组、B组和C组与D组比较,α-SMA和desmin的表达减少,而nephrin和podocin的表达明显增加(P<0.05);C组不仅nephrin和podocin mRNA表达(P<0.05),而且在蛋白表达方面均观察有协同效应。结论:MDIY对早期DN引起的肾功能损害是一种保护作用,可以大大提高与罗格列酮相结合的治疗效果,其机制是通过增加nephrin、podocin的表达和减少α-SMA、desmin的表达,从而推测MDIY具有显著的协同治疗DN作用。七氟烷预处理能改善糖尿病肾病足细胞结构和功能,对围术期外科快速康复有利。 Objective:To expore the effects and mechanism of modified Buyang Huanwu Decoction reducing the risk of kidney damage caused by the early of the diabetic nephropathy(DN)with sevoflurane preconditioning.Methods:Then DN rats were randomly divided into four groups(n=16),MDIY(group A),rosiglitazone(group B),MDIY+rosiglitazone(group C)and normal saline(group D).During the treating cycle,the glucose(GLU)and urine albumin(UAL)were detected continuously.After the treatment of 7 weeks,the rats were sacrificed and the level of GLU,serum creatinine(SCR)and blood urea nitrogen(BUN)were detected in the serum.At the same time,the kidneys were collected and the renal pathological changes were inspected by hematoxylin and eosin(H&E)staining.The expression levels of proteinuria including nephrin,podocin,α-smooth muscle actin(α-SMA)and desmin were evaluated by Real-time PCR and Western blotting.Results:During the treating cycle,GLU and UAL in the A,B and C groups were lower than group D(P<0.01),after 7 weeks the level of GLU,CR and BUN levels in group A,B and C were much lower than group D(P<0.05).Compared with group A and group B,biochemical indexes above mentioned were much lower in group C(P<0.05).Incidences of glomerular disorders,chronic tubulointerstitial injure and glomerular podocyte damage were observed in group A,B,C and D when compared to normal SD rats by H&E staining.However,group C showed optimal improvement of glomerular disorders,chronic tubulointerstitial injure and glomerular podocyte damage.The expression ofα-SMA and desmin decreased,while the expression of nephrin and podocin increased markedly in group A,B and C comparing with group D(P<0.05),which were detected by Real-time PCR and Western blotting.The synergistic effect was observed not only in the mRNA expression of nephrin and podocin in group C(P<0.05),but also in the protein expression.Conclusion:MDIY was proven to be a protective effect in kidney damage caused by DN and could considerably ameliorate the therapeutic efficacy combined with rosiglitazone,which developed a treating role through increasing the expression of nephrin and podocin and decreasing the expression ofα-SMA and desmin.And sevoflurane preconditioning can improve the structure and function of diabetic nephropathy,and it is beneficial to the rapid rehabilitation of perioperative period.
作者 林华阳 刘志宏 曾忱 林斐翎 刘国平 田芳曦 陈明芳 郑京 邱水生 LIN Huayang;LIU Zhihong;ZENG Chen;LIN Feiling;LIU Guoping;TIAN Fangxi;CHENG Mingfang;ZHENG Jing;QIU Shuisheng(The Peoples' Hospital Affiliated to Fujian Uiversity of Ttraditional Chinese Medicine,Fuzhou 350004,Fujian,China;Fujian Uiversity of Traditional Chinese Medicine,Fuzhou 350122,Fujian,China;Fujian Medical University Union Hospital,Fuzhou 350001,Fujian,China)
出处 《辽宁中医药大学学报》 CAS 2019年第8期5-10,共6页 Journal of Liaoning University of Traditional Chinese Medicine
基金 福建省自然科学基金项目(2013J01376) 福建省战略新兴产业应用基础研究项目 福建医学创新科技项目(2014-CX-31)
关键词 糖尿病肾病 加味补阳还五汤 七氟烷 足细胞 diabetic nephropathy modified Buyang Huanwu Decoction sevoflurane podocyte
  • 相关文献

参考文献2

二级参考文献14

  • 1Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998,352:837-53.
  • 2American Diabetes Association. Standards of Medical Care in Diabetes - 2011. Diabetes Care 2011 ,34 Suppl 1 :S 11-61.
  • 3Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et aL A diabetes outcome progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002,25:1737-43.
  • 4Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000,283:1695-702.
  • 5Rosenstock J, Rood J, Cobitz A, Huang C, Garber A. Improvement in glycaemic control with rosiglitazone/metformin fixed-dosecombination therapy in patients with type 2 diabetes with very poor glycaemic control. Diabetes Obes Metab 2006,8:643-9.
  • 6Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metfbrmin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006,8:650-60.
  • 7Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino A J, et al. A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/mefformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-nai've type 2 diabetes mellitus patients. Diabetes Obes Metab 2011 , 13: | 036-46.
  • 8Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, et al. Effects of rosiglitazone, glyburide, and metformin on g-cell function and insulin sensitivity in ADOPT. Diabetes 2011 ,60:1552-60.
  • 9Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with mettbnnin. Intern Med J 2007,37:79-86.
  • 10Li X, Zhang N, Li Y, Shi Y, Li D, Xie Y, et al. Effects of metformin and rosiglitazone on peripheral insulin resistance and B-cell function in obesity: A double-blind, randomized, controlled study. J Int Med Res 2011 ,39:358-65.

共引文献32

同被引文献85

引证文献5

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部